Pharmaceuticals

Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019

* The study results presented at the ERS 2019 as a late breaking abstract demonstrated positive safety and tolerance in healthy volunteers * Data demonstrated LPA inhibition of BBT-877 up to 90% in multiple-ascending dose cohorts SEONGNAM, South Korea and MADRID, Sept. 29, 2019 /PRNewswire/ --...

2019-09-30 06:00 1618

Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal

MELBOURNE, Australia and SYDNEY, Sept. 29, 2019 /PRNewswire/ -- Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been awarded a major grant from the US National Institut...

2019-09-30 05:00 1092
1 ... 304305306307308